Juan Jaen Sells 9,236 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 9,236 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $27.03, for a total value of $249,649.08. Following the sale, the president directly owned 913,004 shares in the company, valued at $24,678,498.12. This trade represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Arcus Biosciences Stock Up 4.9%

NYSE RCUS opened at $30.22 on Friday. The stock has a 50 day moving average price of $24.67 and a 200-day moving average price of $22.95. Arcus Biosciences, Inc. has a one year low of $7.91 and a one year high of $31.44. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.04 and a current ratio of 4.04. The company has a market capitalization of $3.80 billion, a P/E ratio of -9.50 and a beta of 0.85.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The business had revenue of $17.00 million during the quarter, compared to the consensus estimate of $29.48 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The company’s revenue for the quarter was down 39.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.14) EPS. As a group, equities analysts predict that Arcus Biosciences, Inc. will post -3.66 EPS for the current fiscal year.

Institutional Trading of Arcus Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in shares of Arcus Biosciences by 309.4% during the fourth quarter. Wellington Management Group LLP now owns 5,184,509 shares of the company’s stock valued at $123,547,000 after buying an additional 3,918,220 shares during the period. Marshall Wace LLP bought a new position in shares of Arcus Biosciences during the fourth quarter valued at approximately $80,731,000. Suvretta Capital Management LLC raised its holdings in shares of Arcus Biosciences by 40.7% in the fourth quarter. Suvretta Capital Management LLC now owns 5,188,858 shares of the company’s stock worth $123,650,000 after buying an additional 1,500,000 shares during the period. Toronto Dominion Bank purchased a new stake in shares of Arcus Biosciences in the fourth quarter worth approximately $35,380,000. Finally, Vanguard Group Inc. lifted its stake in shares of Arcus Biosciences by 20.1% during the 4th quarter. Vanguard Group Inc. now owns 7,962,874 shares of the company’s stock worth $189,755,000 after acquiring an additional 1,333,421 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RCUS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Monday, April 20th. Truist Financial started coverage on Arcus Biosciences in a research note on Monday, May 18th. They set a “buy” rating and a $35.00 price objective on the stock. Citigroup upped their price objective on Arcus Biosciences from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Wall Street Zen lowered Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group lifted their target price on Arcus Biosciences from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.10.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.